Cargando…
Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease
BACKGROUND: We have demonstrated previously that enzymatically degraded low‐density lipoprotein (eLDL) is an essential causative component for the initiation of atherosclerosis. Here, we investigated the different stages of human aortic valve sclerosis for the presence of eLDL and effectors of the i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845139/ https://www.ncbi.nlm.nih.gov/pubmed/26475297 http://dx.doi.org/10.1161/JAHA.115.002156 |
_version_ | 1782428887966285824 |
---|---|
author | Twardowski, Laura Cheng, Fei Michaelsen, Jens Winter, Stefan Hofmann, Ute Schaeffeler, Elke Müller, Simon Sonnenberg, Maike Steuer, Kristin Ott, German Schwab, Matthias Franke, Ulrich F. W. Torzewski, Michael |
author_facet | Twardowski, Laura Cheng, Fei Michaelsen, Jens Winter, Stefan Hofmann, Ute Schaeffeler, Elke Müller, Simon Sonnenberg, Maike Steuer, Kristin Ott, German Schwab, Matthias Franke, Ulrich F. W. Torzewski, Michael |
author_sort | Twardowski, Laura |
collection | PubMed |
description | BACKGROUND: We have demonstrated previously that enzymatically degraded low‐density lipoprotein (eLDL) is an essential causative component for the initiation of atherosclerosis. Here, we investigated the different stages of human aortic valve sclerosis for the presence of eLDL and effectors of the innate immune system, as well as the interaction of eLDL with isolated valvular interstitial cells/myofibroblasts to discover possible pathways leading to aortic valve sclerosis. METHODS AND RESULTS: Human aortic valvular tissue was obtained from 68 patients undergoing valve replacement surgery. Patients were classified into 3 groups (mild, moderate, or severe aortic valve sclerosis), and clinical data for statistical analysis were gathered from all patients. Immunohistochemical staining demonstrated extensive extracellular deposits of eLDL throughout all grades of aortic valve sclerosis. Complementary analysis of lipid composition revealed higher concentrations of the decisive components of eLDL (ie, unesterified cholesterol and linoleic acid) compared with internal control tissues. Further, the complement component C3d and terminal complement complexes colocalized with eLDL compatible with the proposal that subendothelially deposited eLDL is enzymatically transformed into a complement activator at early stages of valvular cusp lesion development. Gene expression profiles of proteases and complement components corroborated by immunohistochemistry demonstrated an upregulation of the protease cathepsin D (a possible candidate for LDL degradation to eLDL) and the complement inhibitor CD55. Surprisingly, substantial C‐reactive protein expression was not observed before grade 2 aortic valve sclerosis as investigated with microarray analysis, reverse transcription–polymerase chain reaction analysis, and immunohistochemistry. Finally, we demonstrated cellular uptake of eLDL by valvular interstitial cells/myofibroblasts. CONCLUSIONS: The present study is a startup of a hypothesis on the pathogenesis of aortic valve sclerosis declaring extracellular lipoprotein modification, subsequent complement activation, and cellular uptake by valvular interstitial cells/myofibroblasts as integral players. |
format | Online Article Text |
id | pubmed-4845139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48451392016-04-27 Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease Twardowski, Laura Cheng, Fei Michaelsen, Jens Winter, Stefan Hofmann, Ute Schaeffeler, Elke Müller, Simon Sonnenberg, Maike Steuer, Kristin Ott, German Schwab, Matthias Franke, Ulrich F. W. Torzewski, Michael J Am Heart Assoc Original Research BACKGROUND: We have demonstrated previously that enzymatically degraded low‐density lipoprotein (eLDL) is an essential causative component for the initiation of atherosclerosis. Here, we investigated the different stages of human aortic valve sclerosis for the presence of eLDL and effectors of the innate immune system, as well as the interaction of eLDL with isolated valvular interstitial cells/myofibroblasts to discover possible pathways leading to aortic valve sclerosis. METHODS AND RESULTS: Human aortic valvular tissue was obtained from 68 patients undergoing valve replacement surgery. Patients were classified into 3 groups (mild, moderate, or severe aortic valve sclerosis), and clinical data for statistical analysis were gathered from all patients. Immunohistochemical staining demonstrated extensive extracellular deposits of eLDL throughout all grades of aortic valve sclerosis. Complementary analysis of lipid composition revealed higher concentrations of the decisive components of eLDL (ie, unesterified cholesterol and linoleic acid) compared with internal control tissues. Further, the complement component C3d and terminal complement complexes colocalized with eLDL compatible with the proposal that subendothelially deposited eLDL is enzymatically transformed into a complement activator at early stages of valvular cusp lesion development. Gene expression profiles of proteases and complement components corroborated by immunohistochemistry demonstrated an upregulation of the protease cathepsin D (a possible candidate for LDL degradation to eLDL) and the complement inhibitor CD55. Surprisingly, substantial C‐reactive protein expression was not observed before grade 2 aortic valve sclerosis as investigated with microarray analysis, reverse transcription–polymerase chain reaction analysis, and immunohistochemistry. Finally, we demonstrated cellular uptake of eLDL by valvular interstitial cells/myofibroblasts. CONCLUSIONS: The present study is a startup of a hypothesis on the pathogenesis of aortic valve sclerosis declaring extracellular lipoprotein modification, subsequent complement activation, and cellular uptake by valvular interstitial cells/myofibroblasts as integral players. John Wiley and Sons Inc. 2015-10-16 /pmc/articles/PMC4845139/ /pubmed/26475297 http://dx.doi.org/10.1161/JAHA.115.002156 Text en © 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Twardowski, Laura Cheng, Fei Michaelsen, Jens Winter, Stefan Hofmann, Ute Schaeffeler, Elke Müller, Simon Sonnenberg, Maike Steuer, Kristin Ott, German Schwab, Matthias Franke, Ulrich F. W. Torzewski, Michael Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease |
title | Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease |
title_full | Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease |
title_fullStr | Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease |
title_full_unstemmed | Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease |
title_short | Enzymatically Modified Low‐Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease |
title_sort | enzymatically modified low‐density lipoprotein is present in all stages of aortic valve sclerosis: implications for pathogenesis of the disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845139/ https://www.ncbi.nlm.nih.gov/pubmed/26475297 http://dx.doi.org/10.1161/JAHA.115.002156 |
work_keys_str_mv | AT twardowskilaura enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT chengfei enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT michaelsenjens enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT winterstefan enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT hofmannute enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT schaeffelerelke enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT mullersimon enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT sonnenbergmaike enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT steuerkristin enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT ottgerman enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT schwabmatthias enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT frankeulrichfw enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease AT torzewskimichael enzymaticallymodifiedlowdensitylipoproteinispresentinallstagesofaorticvalvesclerosisimplicationsforpathogenesisofthedisease |